Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash & Current Investments (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Cash & Current Investments for 14 consecutive years, with $148.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments rose 74.69% year-over-year to $148.4 million, compared with a TTM value of $729.5 million through Dec 2025, up 758.73%, and an annual FY2025 reading of $156.6 million, down 36.92% over the prior year.
  • Cash & Current Investments was $148.4 million for Q4 2025 at Enanta Pharmaceuticals, down from $156.6 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $375.9 million in Q1 2021 and bottomed at $85.0 million in Q4 2024.
  • Average Cash & Current Investments over 5 years is $218.0 million, with a median of $220.1 million recorded in 2023.
  • Peak annual rise in Cash & Current Investments hit 190.66% in 2024, while the deepest fall reached 74.8% in 2024.
  • Year by year, Cash & Current Investments stood at $160.0 million in 2021, then increased by 7.67% to $172.2 million in 2022, then surged by 95.74% to $337.2 million in 2023, then crashed by 74.8% to $85.0 million in 2024, then soared by 74.69% to $148.4 million in 2025.
  • Business Quant data shows Cash & Current Investments for ENTA at $148.4 million in Q4 2025, $156.6 million in Q3 2025, and $204.1 million in Q2 2025.